摘要
VEGF-A antagonists have revolutionized wet AMD treatment.Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease.Brolucizumab directly inhibits VEGF-A function,providing visual outcomes comparable to aflibercept(an FDA-approved VEGF-A antagonist).Anatomic retinal outcomes including retinal fluid,a marker of disease activity,favored brolucizumab.To view this Bench to Bedisde,open or download the PDF.
出处
《四川生理科学杂志》
2020年第2期185-185,共1页
Sichuan Journal of Physiological Sciences
